文献速递外周动脉疾病

股腘动脉斑块旋切术治疗现状的批判性评价

Critical appraisal of the contemporary use of atherectomy to treat femoropopliteal atherosclerotic disease.
PubMed 文献 · J Vasc Surg · 2021-07-22

技术成功率92.3%,12个月一期通畅率72.6%,踝肱指数从术前0.6改善至术后0.84,但研究异质性大,未显示斑块旋切术优于替代方案。

要点

  • 斑块旋切术治疗股腘动脉病变技术成功率92.3%,12个月一期通畅率72.6%。
  • 远端栓塞、血管穿孔和夹层发生率分别为3.4%、1.9%和4%。
  • 现有证据异质性大,未证明斑块旋切术优于替代方案,需高质量随机对照试验。

核心结论

  • 股腘动脉斑块旋切术可安全完成,踝肱指数适度改善,近四分之三患者维持1年通畅。
  • 但研究异质性大,未证明斑块旋切术优于替代方案,不支持其广泛使用。

研究设计与样本

  • 系统综述与荟萃分析,遵循PRISMA声明,检索MEDLINE、Embase、Cochrane Library和Thompson Web of Sciences至2020年4月5日。

主要发现

  • 斑块旋切组中定向旋切851例,旋转旋切851例,激光旋切201例,轨道旋切78例。
  • 技术成功率92.3%,初始通畅率95.4%,12个月中位随访一期通畅率72.6%。
  • 踝肱指数从术前平均0.6改善至术后平均0.84。
  • 远端栓塞、血管穿孔和夹层发生率分别为3.4%、1.9%和4%。
  • 随访期间大截肢率和死亡率分别为2.2%和3.4%。

临床怎么用

  • 斑块旋切术可作为股腘动脉粥样硬化病变的血管内治疗选择之一,但需权衡其高成本与有限获益证据。
  • 应关注远端栓塞、穿孔和夹层等并发症风险。

局限性

  • 纳入研究异质性大,影响结论的普遍性。
  • 缺乏高质量随机对照试验确定斑块旋切术获益的特定患者和病变特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Atherectomy has become increasingly used as an endovascular treatment of lower extremity atherosclerotic disease in the United States. However, concerns and controversies about its indications and outcomes exist. The goal of the present systematic review and meta-analysis was to investigate the outcomes and complications related to atherectomy to treat femoropopliteal atherosclerotic disease. METHODS: A systematic review in accordance with the recommendations from the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement was performed. Four major scientific repositories (MEDLINE, Embase, the Cochrane Library, and Thompson Web of Sciences) were queried from their inception to April 5, 2020. We reviewed and entered the data in a dedicated dataset. The outcomes included the patency rates, clinical and hemodynamic improvement, and morbidity and mortality associated with atherectomy interventions. RESULTS: Twenty-four studies encompassing 1900 patients met the inclusion criteria for the present study. Of the 1900 patients, 74.3% had presented with Rutherford class 1 to 3 and 25.7% presented with Rutherford class 4 to 6; 1445 patients had undergone atherectomy, and 455 patients had been treated without atherectomy. The atherectomy group had undergone directional atherectomy (n = 851), rotational atherectomy (n = 851), laser atherectomy (n = 201), and orbital atherectomy (n = 78). Most of these patients had also received adjunct treatments, which varied across the studies and included a combination of stenting, balloon angioplasty, or drug-coated balloon angioplasty. Technical success was achieved in 92.3% of the cases. Distal embolization, vessel perforation, and dissection occurred in 3.4%, 1.9%, and 4% of the cases, respectively. The initial patency was 95.4%. At the 12-month median follow-up, the primary patency was 72.6%. The ankle brachial index had improved from a preoperative mean of 0.6 to a postoperative mean of 0.84. The incidence of major amputation and mortality during the follow-up period was 2.2% and 3.4%, respectively. CONCLUSIONS: The results from our review of the reported data suggest that femoropopliteal atherectomy can be completed safely, modestly improving the ankle brachial index and maintaining the 1-year patency in nearly three of four patients. However, these findings were based on heterogeneous studies that skewed the generalizable conclusions about atherectomy's efficacy. Atherectomy places a high cost burden on the healthcare system and is used in the United States at a higher rate than in other countries. Our review of the literature did not demonstrate clear atherectomy superiority to alternatives that would warrant the pervasive and increasing use of this costly technology. Future work should focus on developing high-quality randomized controlled trials to determine the specific patient and lesion characteristics for which atherectomy can add value.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Gupta R, Siada S, Lai S, et al. Critical appraisal of the contemporary use of atherectomy to treat femoropopliteal atherosclerotic disease. J Vasc Surg. 2021. PMID: 34303802. doi:10.1016/j.jvs.2021.07.106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。